Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
Autore:
Buckner, JC; Malkin, MG; Reed, E; Cascino, TL; Reid, JM; Ames, MM; Tong, WPY; Lim, S; Figg, WD;
Indirizzi:
Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA Mayo Clin & MayoFdn Rochester MN USA 55905 ncol, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 urol, Rochester, MN 55905 USA Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA Mem Sloan Kettering Canc Ctr, Pharmaceut Analyt Lab, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA NCI, Clin Pharmacol Branch, Div Clin Sci, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892 ol Branch, Div Clin Sci, Bethesda, MD 20892 USA
Titolo Testata:
MAYO CLINIC PROCEEDINGS
fascicolo: 2, volume: 74, anno: 1999,
pagine: 137 - 145
SICI:
0025-6196(199902)74:2<137:PISOAA>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHENYLACETATE; CANCER; CELLS; DIFFERENTIATION; INHIBITION; PHENYLKETONURIA; DERIVATIVES; GROWTH; ALPHA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Buckner, JC Mayo Clin & Mayo Fdn, Dept Oncol, 200 1st St SW, Rochester, MN55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 55905 USA
Citazione:
J.C. Buckner et al., "Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma", MAYO CLIN P, 74(2), 1999, pp. 137-145

Abstract

Objective: To assess the pharmacokinetics, toxicity, and efficacy of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261),Design: We initiated a phase II trial in order to determine whether evidence of antitumor activity of A10 and AS2-1 could be documented,Material and Methods: Patients with anaplastic astrocytoma or glioblastomamultiforme recurring after radiation therapy were eligible for enrollment in the trial, Patients received escalating doses of A10 and AS2-1 by multiple intermittent intravenous injections with use of a portable programmable pump to the target daily dose of 1.0 g/kg for A10 and of 0.4 g/kg for AS2-1,Results: Nine patients were treated, in six of whom the treatment responsewas assessable in accordance with protocol stipulations, No patient demonstrated tumor regression. Reversible grade 2 or 3 neurocortical toxicity, consisting of transient somnolence, confusion, and exacerbation of an underlying seizure disorder, was noted in five patients, Mean steady-state plasma concentrations of phenylacetate and phenylacetylglutamine after escalation to the target doses of A10 and AS2-1 were 177 +/- 101 mu g/mL and 302 +/- 102 mu g/mL, respectively, Patients who exhibited confusion tended to have higher phenylacetate levels,Conclusion: Although we could not confirm any tumor regression in patientsin this study, the small sample size precludes definitive conclusions about treatment efficacy. Antineoplaston-related toxicity was acceptable in most patients with appropriate dose modification, although severe neurocortical toxicity may occur. Steady-state plasma concentrations of phenylacetate with use of A10 and AS2-1 were similar to those reported with use of similardoses of phenylacetate alone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 15:02:16